(Q49216363)

English

Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C.

scientific article published in July 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 February 2018

http://europepmc.org/abstract/MED/11454179

Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C. (English)

1 reference

Europe PubMed Central

19 February 2018

http://europepmc.org/abstract/MED/11454179

amantadine sulfate

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

19 February 2018

http://europepmc.org/abstract/MED/11454179

author name string

G Teuber

1

1 reference

Europe PubMed Central

19 February 2018

http://europepmc.org/abstract/MED/11454179

U Naumann

3

1 reference

Europe PubMed Central

19 February 2018

http://europepmc.org/abstract/MED/11454179

J Raedle

4

1 reference

Europe PubMed Central

19 February 2018

http://europepmc.org/abstract/MED/11454179

S Brinkmann

5

1 reference

Europe PubMed Central

19 February 2018

http://europepmc.org/abstract/MED/11454179

U Hopf

6

1 reference

Europe PubMed Central

19 February 2018

http://europepmc.org/abstract/MED/11454179

S Zeuzem

7

1 reference

Europe PubMed Central

19 February 2018

http://europepmc.org/abstract/MED/11454179

publication date

1 July 2001

1 reference

Europe PubMed Central

19 February 2018

http://europepmc.org/abstract/MED/11454179

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

19 February 2018

http://europepmc.org/abstract/MED/11454179

8

1 reference

Europe PubMed Central

19 February 2018

http://europepmc.org/abstract/MED/11454179

4

1 reference

Europe PubMed Central

19 February 2018

http://europepmc.org/abstract/MED/11454179

276-283

1 reference

Europe PubMed Central

19 February 2018

http://europepmc.org/abstract/MED/11454179

Hepatitis C virus infection is associated with the development of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00297.X

21 January 2018

The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00297.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00297.X

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00297.X

21 January 2018

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00297.X

21 January 2018

Inhibition of uncoating of fowl plague virus by l-adamantanamine hydrochloride

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00297.X

21 January 2018

Arenaviruses: inhibition by amantadine hydrochloride.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00297.X

21 January 2018

Inhibition of dengue virus replication by amantadine hydrochloride

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00297.X

21 January 2018

A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00297.X

21 January 2018

Classification of chronic hepatitis: diagnosis, grading and staging

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00297.X

21 January 2018

Evaluation and comparison of different hepatitis C virus genotyping and serotyping assays

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00297.X

21 January 2018

In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00297.X

21 January 2018

Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00297.X

21 January 2018

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00297.X

21 January 2018

Therapy of hepatitis C: overview

1 reference

https://pubmed.ncbi.nlm.nih.gov/11454179

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo

1 reference

https://pubmed.ncbi.nlm.nih.gov/11454179

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical evaluation of a new polymerase chain reaction assay (Amplicor HCV) for detection of hepatitis C virus.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11454179

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/11454179

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The molecular basis of the specific anti-influenza action of amantadine

1 reference

https://pubmed.ncbi.nlm.nih.gov/11454179

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/11454179

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11454179

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro inhibition of rubella virus by 1-adamantanamine hydrochloride

1 reference

https://pubmed.ncbi.nlm.nih.gov/11454179

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of amantadine on mouse hepatitis virus replication

1 reference

https://pubmed.ncbi.nlm.nih.gov/11454179

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alpha retreatment in chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11454179

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of chronic hepatitis C with amantadine

1 reference

https://pubmed.ncbi.nlm.nih.gov/11454179

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/11454179

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://pubmed.ncbi.nlm.nih.gov/11454179

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block

1 reference

https://pubmed.ncbi.nlm.nih.gov/11454179

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1046/J.1365-2893.2001.00297.X

1 reference

Europe PubMed Central

19 February 2018

http://europepmc.org/abstract/MED/11454179

1 reference

Europe PubMed Central

19 February 2018

http://europepmc.org/abstract/MED/11454179

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q49216363&oldid=1590375533"